Advertisement
Research Article Free access | 10.1172/JCI110434
Find articles by Sacks, S. in: JCI | PubMed | Google Scholar
Find articles by Merigan, T. in: JCI | PubMed | Google Scholar
Find articles by Kaminska, J. in: JCI | PubMed | Google Scholar
Find articles by Fox, I. in: JCI | PubMed | Google Scholar
Published January 1, 1982 - More info
To assess for possible inhibition of cellular transmethylation during adenine arabinoside (ara-A) therapy, S-adenosylhomocysteine hydrolase activity was analyzed in 10 patients with chronic hepatitis B virus infection. In six patients receiving ara-A, enzyme activity was suppressed to 0-2% of control erythrocyte enzyme activity. This decrease in enzyme activity was evident within 4 h of starting the drug infusion and continued for 7 d after cessation of therapy. S-adenosylhomocysteine hydrolase activity of peripheral mononuclear cells was also measured in two patients receiving ara-A. Suppression to as low as 3.5% of pretreatment levels was found; however, marked fluctuations with partial return of enzyme activity during therapy was also observed in mononuclear cells. Inhibition of an enzyme involved in transmethylation reactions was observed in patients during ara-A therapy. This could contribute to the side effects and antiviral properties of ara-A.